Abiraterone is mainly used to treat prostate cancer, and its survival is about 1 to 3 years after taking abiraterone. In phase III clinical trials, after taking abiraterone for prostate cancer patients without chemotherapy, the progression-free survival was 16.5 months and the overall survival was 34.7 months; after chemotherapy or taking abiraterone when the effect is not optimistic, the progression-free survival was 10.2 months and the overall survival was 15.8 months. However, the above data are for reference only and the specific situation varies from person to person. Abiraterone may cause adverse reactions such as hypertension, hepatic and renal impairment, hypokalemia, peripheral edema, etc. The drug should be used according to the doctor’s instructions. The drug is contraindicated for those who are allergic to Abiraterone, pregnant women, and those with severe hepatic impairment.